Compare PTCT & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTCT | BXSL |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.5B |
| IPO Year | 2006 | 2018 |
| Metric | PTCT | BXSL |
|---|---|---|
| Price | $66.77 | $23.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $80.94 | $27.31 |
| AVG Volume (30 Days) | 1.0M | ★ 2.7M |
| Earning Date | 05-12-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 13.02% |
| EPS Growth | ★ 264.48 | N/A |
| EPS | ★ 7.78 | 2.46 |
| Revenue | ★ $264,734,000.00 | N/A |
| Revenue This Year | N/A | $2.05 |
| Revenue Next Year | $21.65 | N/A |
| P/E Ratio | ★ $8.29 | $9.62 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $35.95 | $23.30 |
| 52 Week High | $87.50 | $33.73 |
| Indicator | PTCT | BXSL |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 38.46 |
| Support Level | $61.43 | $23.30 |
| Resistance Level | $68.44 | $27.04 |
| Average True Range (ATR) | 2.62 | 0.63 |
| MACD | 0.19 | 0.02 |
| Stochastic Oscillator | 55.17 | 15.82 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.